Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 97,147

Document Document Title
WO/2014/163162A1
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...  
WO/2014/165070A1
The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or...  
WO/2014/163518A1
The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient.  
WO/2014/163416A1
The present invention relates to a composition for life extension and particularly to a composition for life extension containing syringaresinol. The composition according to the present invention can extend the life of an individual by ...  
WO/2014/164756A1
Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.  
WO/2014/165043A1
The described invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome an...  
WO/2014/163132A1
The present invention addresses the problem of proving a stabilized solid composition of an amino carboxylate salt. The solution is a medicinal solid composition containing [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/165065A1
The present invention is directed to compounds of Formula I: wherein X is CR1 or N; Y is CR2 or N; Z is NH or O; R1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R2 is H, alkyl, or halo; R3 is H, alkyl, alkoxy,...  
WO/2014/161801A1
The present invention relates to compounds of general formula I wherein R1 is halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, CF3 or lower alkyl; R3 is...  
WO/2014/163146A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 represents a group represented by formula (II), a group represented by formula (III) or a group represented by formula (IV); and R2 ...  
WO/2014/154895A1
The present invention relates to novel compounds of Formula (I), and their use in therapeutic treatments.  
WO/2014/157437A1
A propellane derivative represented by general formula (I) (wherein R1 represents a hydrogen atom, a C1-6 alkyl group, a cycloalkylalkyl group (wherein the number of carbon atoms in a cycloalkyl moiety is 3 to 6 and the number of carbon ...  
WO/2014/157860A1
The present invention provides a process for the preparation of high-purity olanzapine with high yield and a process for the preparation of olanzapine crystalline Form II, which are industrially applicable. The preparation processes acco...  
WO/2014/154179A1
The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.  
WO/2014/155387A1
The present invention relates to extended release dosage forms of weakly basic drugs. Particularly the present invention is related to extended release dosage forms of quetiapine or pharmaceutically acceptable salts thereof.  
WO/2014/157047A1
The present invention relates to a therapeutic agent for neurodegenerative diseases, which contains a compound represented by formula (I) or a salt thereof. (In the formula, Ar1 represents an aromatic group; X represents a single bond or...  
WO/2014/159662A1
The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biologica...  
WO/2014/158916A1
The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and and their use in a wide range o...  
WO/2014/160811A1
The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035and GDNF for the treatment of both large and small fiber neuropathies.  
WO/2014/157803A1
The present invention relates to a composition for a GABAA-benzodiazepine receptor activation, which includes, as an active ingredient, an extract of at least one shellfish selected from among Mytilus edulis, Tegillarca granosa and Merce...  
WO/2014/160197A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2014/154131A1
Provided are a caffeoyl substituted pentacyclic triterpene derivative as represented by formula (I) and pharmaceutical composition containing the same. Also provided are uses of the derivative in the preparation of drugs or health-care p...  
WO/2014/158165A1
A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and...  
WO/2014/160077A1
This disclosure relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists (opioid antagonists that treats pain by blocking Toll-like receptor 4 (TLR4)) and dextro enantiomers thereof for the treatment ...  
WO/2014/158998A1
The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection an...  
WO/2014/157158A1
Provided is a compound with strong human S1P2 antagonistic activity in order to develop drug products that are useful for treating S1P2 mediated disorders such as disorders that cause constriction of blood vessels, fibrosing disease, res...  
WO/2014/160102A1
The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorde...  
WO/2014/154158A1
A traditional Chinese medicine composition for treating depression, and a preparation method therefor. Raw pharmaceutical ingredients of the traditional Chinese medicine composition comprise epimedium, prepared fleece-flower roots, and a...  
WO/2014/158059A1
The essence of the invention consists in a method for treating addiction, comprising pharmacotherapy with the use of medicinal homeopathic remedies, and also reflexotherapy with the stimulation of biologically active points (BAP) in comb...  
WO/2014/158547A1
This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metab...  
WO/2014/155332A1
This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 ma...  
WO/2014/155056A1
A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric...  
WO/2014/157635A1
The purpose of the present invention is to provide a drug that demonstrates a pharmaceutical effect by having high mobility to the mid-brain and converting to bumetanide in the mid-brain, which is the primary site of epilepsy. The presen...  
WO/2014/157569A1
Provided is a compound having an excellent JAK-inhibiting effect, the compound being is useful as an agent for the prevention or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syn...  
WO/2014/154896A1
The present invention relates to novel compounds of Formula I, and their use in therapeutic treatments.  
WO/2014/160181A1
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2014/157380A1
Provided is a means whereby wounds or organ fibrosis can be easily treated within a short period of time. A therapeutic agent for wounds or fibrosis, said therapeutic agent comprising a substance capable of specifically inhibiting the ex...  
WO/2014/160423A1
The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least...  
WO/2014/155184A1
A method for treating Parkinson's disease in a mammal in need thereof is disclosed. The method comprises administering to the mammal an effective amount of a compound of any one of Structural Formulas (I-III), or a pharmaceutically accep...  
WO/2014/157107A1
[Problem] To provide a polypeptide which has highly homogeneous sialylated sugar chains attached thereto and has an interferon β activity. [Solution] A sugar chain-containing polypeptide that is selected from the group consisting of (1)...  
WO/2014/155186A1
The invention relates to a food supplement comprising isomaltulose, whey protein concentrate, linseed, whey mineral complex, short-chain fructooligosaccharides, lactoferrin, and vitamin B6. This food supplement was developed to be used a...  
WO/2014/160502A1
This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders ...  
WO/2014/154897A1
The present invention relates to novel compounds of Formula (I) and their use in therapeutic treatments.  
WO/2014/159591A1
The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or ind...  
WO/2014/155351A1
A composition comprises as active ingredient an extract of a plant or plants from the Mesembryanthemaceae family, such as Mesembryanthemum tortuosum, having an alkaloid profile comprising at least 70% (w/w) stabilized mesembrine. The ext...  
WO/2014/160480A1
3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.  
WO/2014/147178A1
The present invention relates to Histone deacetylases 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative diseas...  
WO/2014/151752A1
Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent ...  
WO/2014/148574A1
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...  

Matches 51 - 100 out of 97,147